Hospital

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses how asciminib has impacted the treatment landscape for chronic myeloid leukemia.

New data are being presented at ASH 2021 regarding the durable efficacy of acalabrutinib in chronic lymphocytic leukemia.

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses some of the challenges and risk of ibrutinib as treatment for CLL.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses new longer-term efficacy and safety data from the pivotal phase 3 ASCEMBL study.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed the current burden of C. diff infection and recurrent C. diff infection.

The combination therapy of ibrutinib and venetoclax was superior to chlorambucil and obinutuzumab in terms of undetectable minimal residual disease responses in elderly or unfit patients with previously untreated chronic lymphocytic leukemia.

According to the trial results, these responses appear durable, with a target dose-dependent increase in overall response rate without any increase in the rate of cytokine release syndrome.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, addressed the risk factors for C. diff infection and recurrent C. diff infection.

In a phase 1b trial, the combination therapy of acalabrutinib, venetoclax, and rituximab had a 100% clinical response rate and was well-tolerated in patients with treatment-naïve mantle cell lymphoma.

An FDA decision regarding Merck's COVID-19 oral antiviral is imminent, but a recent CMS decision could limit patient access.

Apotex, Sandoz, and Taro allegedly cause an increase in drug costs for federal health care programs and beneficiaries.

A panel recently re-convened recently to develop guidance for AmpC-bearing gram-negative pathogens.

Pharmacists can help patients manage their medications and any adverse effects, and can also educate patients about their condition and treatments.

FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements.

The car crashes occurring on December 24 and December 31 due to impaired driving account for approximately 50% of all traffic fatalities a year.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, addressed the relationship between gut microbiome and C. diff infection.

Pembrolizumab is the first anti-PD-1/anti-PD-L1 therapy to demonstrate a recurrence-free survival benefit in the adjuvant setting for melanoma.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discusses the current treatment strategies for C. diff infection and recurrent C. diff infection, as well as the efficacy and safety of these treatments.

In an interview with Pharmacy Times, Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, explains what the gut-brain axis is and how microbiome impacts this connection.

Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed the role of the microbiome in overall patient health and recurrent Clostridioides difficile infection.

Lodise said that one of the notable takeaways is the de-prioritization of polymyxins for the treatment of these infections.

Clonidine, Estradiol, Fentanyl, and Scopolamine are involved most frequently, an ISMP review shows.

Daratumumab continued to demonstrate deep and durable responses, including improvements to stringent complete response (sCR) rates and minimal residual disease (MRD)-negativity.

Studies are currently underway to determine the impact of the Omicron COVID-19 variant on the long-acting antibody combination.

Saol Therapeutics also announces the acquisition of 4 plasma-derived hyperimmune products by Kamada, which will be invested to help launch Lyvispah and other pipeline developments.

Axicabtagene ciloleucel (Yescarta) was the first CAR T-cell immunotherapy to be approved for relapsed or refractory large B-cell lymphoma.

Fulvestrant is also the only SERD approved for patients with breast cancer, according to the researchers.

Pharmacists can play an important role in avoiding common medication errors for patients receiving direct oral anticoagulants.